The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including:
- Granting of additional patents for the company’s HER-Vaxx Immunotherapy in China and South Korea;
- Completion of Phase 1a trial of immunotherapy PD1-Vaxx;
- US Food and Drug Administration (FDA) consent for clinical trials for its oncology treatments.
In recent years the market capitalisation of Imugene Ltd has increased significantly to over $2 Billion AUD.
To see if your company is eligible for the R&D Tax Offset, fill out our eligibility form here.